Kintara Therapeutics, Inc. (KTRA) News

Kintara Therapeutics, Inc. (KTRA): $7.54

0.51 (-6.31%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add KTRA to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#231 of 385

in industry

Filter KTRA News Items

KTRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KTRA News Highlights

  • KTRA's 30 day story count now stands at 2.
  • Over the past 2 days, the trend for KTRA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest KTRA News From Around the Web

Below are the latest news stories about KINTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate KTRA as an investment opportunity.

Kintara Therapeutics Announces Review of Strategic Alternatives

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value.

Yahoo | December 7, 2023

Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it received notice from the Staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the "Rule"). The Rule requires a minimum $2,500,000 stockholders

Yahoo | December 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news worth reading about on Wednesday!

William White on InvestorPlace | November 15, 2023

Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update.

Yahoo | November 13, 2023

Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the curre

Yahoo | October 31, 2023

Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present at the 8th Annual Dawson James Small Cap Growth Conference on Thursday, October 12, 2023 at 10:30 am ET.

Yahoo | October 11, 2023

Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its President and CEO, Robert E. Hoffman will present in the LD Micro Main Event XVI Conference on Wednesday, October 4, 2023 at 11:30 am PT at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Yahoo | October 2, 2023

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam. Presented on September 23, the poster focused on two patient cases from Kintara's Phase 2 study evaluating the safety and tolerability of VAL-083 when administered concurrentl

Yahoo | September 25, 2023

Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand Hotel in Jupiter, FL. Dawson James’ flagship Small Cap Growth Conference brings together senior leadership from over 30 of the most innovative companies at the forefront of healthcare, technology and consu

Yahoo | September 21, 2023

Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2023 and provided a corporate update.

Yahoo | September 18, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!